Post TACE syndrome, Post embolization syndrome HCC, Post TACE syndrome, Post embolization syndrome , N-acetylcysteine
Conditions
Interventions
Participants will receive 1,200 mg of NAC starting 1 day before TACE in the ward. After the procedure, they will receive 600 mg of NAC every 12 hours for a total of 4 doses following the procedure.,Pa
Experimental Drug,No Intervention No treatment
N-acetylcysteine,No NAC
Sponsors
Faculty of medicine siriraj hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Age 18 to 80 years old 2. Diagnosed with HCC (Hepatocellular Carcinoma) with evidence from a pathologist or radiological images consistent with HCC (according to the Liver Cancer Care Guidelines in Thailand, 2564). 3. Treated with TACE (Transarterial Chemoembolization). 4. Informed and Consent
Exclusion criteria
Exclusion criteria: 1.Patients who are pregnant or breastfeeding. 2.Patients with severe or uncontrolled comorbidities. 3.Patients with other cancers in addition to liver cancer. 4.Pateints with a history of allergy to N-acetylcysteine. 5.Patients who have used N-acetylcysteine within 2 weeks before starting the study. 6. Patients with history of using corticosteroids while participating in the study. 7. Abnormal liver function test results (AST/ALT > 3 times the upper normal limit)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Post embolization syndrome 48 hours Fever, Liver function test, Southwest Oncology Group (SWOG) toxicity code, Common Terminology Criteria for Adverse Events (CTCAE) [version 5] | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse event 48 hours patient self report, medical record,decompensated liver cirrhosis 2 weeks Liver function test, Coagulogram, medical record | — |
Countries
Thailand
Contacts
Public ContactSupot Nimanong
Siriraj hospital
Outcome results
None listed